Charles River Laboratories Intl. Inc vs Invesco Solar ETF — how do they compare? Charles River Laboratories Intl. Inc trades at $301.4 (market cap $14.23B), while Invesco Solar ETF trades at $43.67 (market cap $894.08M). The key difference: Charles River Laboratories Intl. Inc is far larger — about 15.9× Invesco Solar ETF's market cap, and Charles River Laboratories Intl. Inc is trading nearer its 52-week high, Invesco Solar ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Charles River Laboratories Intl. Inc for 33 Days and Invesco Solar ETF for 34 Days on average.
| CRL | TAN | |
|---|---|---|
Market Cap | $14.23B | $894.08M |
Volume | 1,176,885 | 370,994 |
Sector | Health | Sector/Thematic |
52-Week High | $310.77 | $73.95 |
52-Week Low | $149.93 | $43.00 |
Typical Hold Time | 33 Days | 34 Days |
Enterprise Value | $17.06B | — |
Signals from Pluang's Aura AI — not financial advice
Charles River Laboratories (CRL) trades at $301.79, up 0.5% with strong analyst support (73% buy ratings) and a $305.50 consensus target. The stock shows bullish technical momentum above key support levels, though fundamentals reveal challenges with negative net income margins (-5.96%) and elevated P/E ratio (684.85). Recent quarterly earnings beats and a new 2030 growth strategy provide optimism, but profitability concerns persist amid flat revenue trends.
The outlook balances near-term technical strength against fundamental headwinds. Investment opportunity lies in execution of the 5-7% growth target and $300M savings plan, while risks include sustained negative profitability, high debt levels ($2.24B), and margin pressure. Current price near resistance at $304 suggests limited upside without fundamental improvement.
TAN (Invesco Solar ETF) trades at $43.75, up 0.51% with bearish technical signals from moving averages. The solar sector faces headwinds from high borrowing costs impacting project financing, as recent news highlights sector volatility. Technical indicators show 16 sell signals versus 1 buy, with key resistance at $44 and support at $43. The ETF's expense ratio of 0.7% is higher than broader energy alternatives, contributing to its underperformance versus the S&P 500 over five years.
Outlook remains cautious due to sector-specific risks including interest rate sensitivity and market saturation concerns. Investment opportunity exists for long-term renewable energy exposure, but risks include policy uncertainty, cost pressures, and competitive ETF alternatives with lower fees. The bearish technical setup suggests near-term pressure despite potential long-term energy transition tailwinds.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
Read more on CRL →TAN is a thematic ETF that tracks the MAC Global Solar Energy Index. It provides targeted exposure to the global solar industry, including manufacturers of solar panels, installers, and component suppliers like Enphase and First Solar.
Read more on TAN →